PMC:7299399 / 4598-6100 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T7","span":{"begin":143,"end":149},"obj":"Body_part"},{"id":"T8","span":{"begin":332,"end":337},"obj":"Body_part"},{"id":"T9","span":{"begin":533,"end":538},"obj":"Body_part"},{"id":"T10","span":{"begin":540,"end":546},"obj":"Body_part"},{"id":"T11","span":{"begin":548,"end":551},"obj":"Body_part"},{"id":"T12","span":{"begin":574,"end":579},"obj":"Body_part"},{"id":"T13","span":{"begin":761,"end":767},"obj":"Body_part"},{"id":"T14","span":{"begin":1057,"end":1062},"obj":"Body_part"},{"id":"T15","span":{"begin":1152,"end":1157},"obj":"Body_part"},{"id":"T16","span":{"begin":1257,"end":1264},"obj":"Body_part"},{"id":"T17","span":{"begin":1429,"end":1436},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma228738"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma54448"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma50801"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma84116"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"9 are fever (85.6%), cough (68.7%), and fatigue (39.4%). Other less common symptoms include dyspnea, headache, loss of appetite, panting, sore throat, vomiting, diarrhea, rhinorrhea, and abdominal pain. The severity of disease in patients depends mainly on the presence of comorbidities such as hypertension, diabetes, and coronary heart disease.12,13 The incubation period is reported to be between 5 and 14 days before disease onset.14 Recent reports indicate that some COVID-19 patients exhibit damage in other organs such as the heart, kidney, eye (conjunctivitis), and brain (encephalitis).15−18 The race is on to develop drugs and treatment options to combat COVID-19, harnessing all of the tools and technologies modern molecular medicine can offer.\nThe genome of SARS-CoV-2 has been fully sequenced19 and shows a high degree of similarity in key genes with other coronaviruses causing respiratory diseases such as SARS-CoV.20 Based on knowledge gathered during the SARS-CoV epidemic, a key target of the virus includes the surface receptor in human cells, angiotensin-converting enzyme II (ACE2), which is required for efficient uptake in host cells.19,21−23\nThe C-terminal domain (i.e., receptor-binding domain of the envelope-embedded spike (S) 1 protein) of SARS-CoV-2 binds ACE2. The molecular details of this interaction have been provided by solving the crystal structure of the complex.24 Because binding of the S protein to ACE2 is critical for the first steps of infection, the most co"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T2","span":{"begin":143,"end":149},"obj":"Body_part"},{"id":"T3","span":{"begin":332,"end":337},"obj":"Body_part"},{"id":"T4","span":{"begin":514,"end":520},"obj":"Body_part"},{"id":"T5","span":{"begin":533,"end":538},"obj":"Body_part"},{"id":"T6","span":{"begin":540,"end":546},"obj":"Body_part"},{"id":"T7","span":{"begin":548,"end":551},"obj":"Body_part"},{"id":"T8","span":{"begin":574,"end":579},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0000341"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"},{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0000970"},{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0000955"}],"text":"9 are fever (85.6%), cough (68.7%), and fatigue (39.4%). Other less common symptoms include dyspnea, headache, loss of appetite, panting, sore throat, vomiting, diarrhea, rhinorrhea, and abdominal pain. The severity of disease in patients depends mainly on the presence of comorbidities such as hypertension, diabetes, and coronary heart disease.12,13 The incubation period is reported to be between 5 and 14 days before disease onset.14 Recent reports indicate that some COVID-19 patients exhibit damage in other organs such as the heart, kidney, eye (conjunctivitis), and brain (encephalitis).15−18 The race is on to develop drugs and treatment options to combat COVID-19, harnessing all of the tools and technologies modern molecular medicine can offer.\nThe genome of SARS-CoV-2 has been fully sequenced19 and shows a high degree of similarity in key genes with other coronaviruses causing respiratory diseases such as SARS-CoV.20 Based on knowledge gathered during the SARS-CoV epidemic, a key target of the virus includes the surface receptor in human cells, angiotensin-converting enzyme II (ACE2), which is required for efficient uptake in host cells.19,21−23\nThe C-terminal domain (i.e., receptor-binding domain of the envelope-embedded spike (S) 1 protein) of SARS-CoV-2 binds ACE2. The molecular details of this interaction have been provided by solving the crystal structure of the complex.24 Because binding of the S protein to ACE2 is critical for the first steps of infection, the most co"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T22","span":{"begin":138,"end":149},"obj":"Disease"},{"id":"T23","span":{"begin":161,"end":169},"obj":"Disease"},{"id":"T24","span":{"begin":295,"end":307},"obj":"Disease"},{"id":"T25","span":{"begin":309,"end":317},"obj":"Disease"},{"id":"T26","span":{"begin":323,"end":345},"obj":"Disease"},{"id":"T27","span":{"begin":332,"end":345},"obj":"Disease"},{"id":"T28","span":{"begin":472,"end":480},"obj":"Disease"},{"id":"T29","span":{"begin":553,"end":567},"obj":"Disease"},{"id":"T30","span":{"begin":581,"end":593},"obj":"Disease"},{"id":"T31","span":{"begin":665,"end":673},"obj":"Disease"},{"id":"T32","span":{"begin":771,"end":779},"obj":"Disease"},{"id":"T33","span":{"begin":893,"end":913},"obj":"Disease"},{"id":"T34","span":{"begin":922,"end":930},"obj":"Disease"},{"id":"T35","span":{"begin":973,"end":981},"obj":"Disease"},{"id":"T36","span":{"begin":1269,"end":1277},"obj":"Disease"},{"id":"T37","span":{"begin":1480,"end":1489},"obj":"Disease"}],"attributes":[{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0002258"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0005010"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005267"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0003799"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0005087"},{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"9 are fever (85.6%), cough (68.7%), and fatigue (39.4%). Other less common symptoms include dyspnea, headache, loss of appetite, panting, sore throat, vomiting, diarrhea, rhinorrhea, and abdominal pain. The severity of disease in patients depends mainly on the presence of comorbidities such as hypertension, diabetes, and coronary heart disease.12,13 The incubation period is reported to be between 5 and 14 days before disease onset.14 Recent reports indicate that some COVID-19 patients exhibit damage in other organs such as the heart, kidney, eye (conjunctivitis), and brain (encephalitis).15−18 The race is on to develop drugs and treatment options to combat COVID-19, harnessing all of the tools and technologies modern molecular medicine can offer.\nThe genome of SARS-CoV-2 has been fully sequenced19 and shows a high degree of similarity in key genes with other coronaviruses causing respiratory diseases such as SARS-CoV.20 Based on knowledge gathered during the SARS-CoV epidemic, a key target of the virus includes the surface receptor in human cells, angiotensin-converting enzyme II (ACE2), which is required for efficient uptake in host cells.19,21−23\nThe C-terminal domain (i.e., receptor-binding domain of the envelope-embedded spike (S) 1 protein) of SARS-CoV-2 binds ACE2. The molecular details of this interaction have been provided by solving the crystal structure of the complex.24 Because binding of the S protein to ACE2 is critical for the first steps of infection, the most co"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T34","span":{"begin":332,"end":337},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T35","span":{"begin":332,"end":337},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T36","span":{"begin":332,"end":337},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T37","span":{"begin":332,"end":337},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T38","span":{"begin":514,"end":520},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T39","span":{"begin":533,"end":538},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T40","span":{"begin":533,"end":538},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T41","span":{"begin":533,"end":538},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T42","span":{"begin":533,"end":538},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T43","span":{"begin":540,"end":546},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T44","span":{"begin":540,"end":546},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T45","span":{"begin":540,"end":546},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T46","span":{"begin":548,"end":551},"obj":"http://www.ebi.ac.uk/efo/EFO_0000827"},{"id":"T47","span":{"begin":574,"end":579},"obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"T48","span":{"begin":574,"end":579},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T49","span":{"begin":598,"end":600},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T50","span":{"begin":782,"end":785},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T51","span":{"begin":819,"end":820},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T52","span":{"begin":854,"end":859},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T53","span":{"begin":992,"end":993},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T54","span":{"begin":1012,"end":1017},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T55","span":{"begin":1051,"end":1062},"obj":"http://purl.obolibrary.org/obo/CLO_0053065"},{"id":"T56","span":{"begin":1152,"end":1157},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T57","span":{"begin":1251,"end":1256},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"}],"text":"9 are fever (85.6%), cough (68.7%), and fatigue (39.4%). Other less common symptoms include dyspnea, headache, loss of appetite, panting, sore throat, vomiting, diarrhea, rhinorrhea, and abdominal pain. The severity of disease in patients depends mainly on the presence of comorbidities such as hypertension, diabetes, and coronary heart disease.12,13 The incubation period is reported to be between 5 and 14 days before disease onset.14 Recent reports indicate that some COVID-19 patients exhibit damage in other organs such as the heart, kidney, eye (conjunctivitis), and brain (encephalitis).15−18 The race is on to develop drugs and treatment options to combat COVID-19, harnessing all of the tools and technologies modern molecular medicine can offer.\nThe genome of SARS-CoV-2 has been fully sequenced19 and shows a high degree of similarity in key genes with other coronaviruses causing respiratory diseases such as SARS-CoV.20 Based on knowledge gathered during the SARS-CoV epidemic, a key target of the virus includes the surface receptor in human cells, angiotensin-converting enzyme II (ACE2), which is required for efficient uptake in host cells.19,21−23\nThe C-terminal domain (i.e., receptor-binding domain of the envelope-embedded spike (S) 1 protein) of SARS-CoV-2 binds ACE2. The molecular details of this interaction have been provided by solving the crystal structure of the complex.24 Because binding of the S protein to ACE2 is critical for the first steps of infection, the most co"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T15","span":{"begin":627,"end":632},"obj":"Chemical"},{"id":"T16","span":{"begin":737,"end":745},"obj":"Chemical"},{"id":"T17","span":{"begin":1064,"end":1075},"obj":"Chemical"},{"id":"T18","span":{"begin":1094,"end":1096},"obj":"Chemical"},{"id":"T19","span":{"begin":1257,"end":1264},"obj":"Chemical"},{"id":"T20","span":{"begin":1429,"end":1436},"obj":"Chemical"}],"attributes":[{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"9 are fever (85.6%), cough (68.7%), and fatigue (39.4%). Other less common symptoms include dyspnea, headache, loss of appetite, panting, sore throat, vomiting, diarrhea, rhinorrhea, and abdominal pain. The severity of disease in patients depends mainly on the presence of comorbidities such as hypertension, diabetes, and coronary heart disease.12,13 The incubation period is reported to be between 5 and 14 days before disease onset.14 Recent reports indicate that some COVID-19 patients exhibit damage in other organs such as the heart, kidney, eye (conjunctivitis), and brain (encephalitis).15−18 The race is on to develop drugs and treatment options to combat COVID-19, harnessing all of the tools and technologies modern molecular medicine can offer.\nThe genome of SARS-CoV-2 has been fully sequenced19 and shows a high degree of similarity in key genes with other coronaviruses causing respiratory diseases such as SARS-CoV.20 Based on knowledge gathered during the SARS-CoV epidemic, a key target of the virus includes the surface receptor in human cells, angiotensin-converting enzyme II (ACE2), which is required for efficient uptake in host cells.19,21−23\nThe C-terminal domain (i.e., receptor-binding domain of the envelope-embedded spike (S) 1 protein) of SARS-CoV-2 binds ACE2. The molecular details of this interaction have been provided by solving the crystal structure of the complex.24 Because binding of the S protein to ACE2 is critical for the first steps of infection, the most co"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T5","span":{"begin":6,"end":11},"obj":"Phenotype"},{"id":"T6","span":{"begin":21,"end":26},"obj":"Phenotype"},{"id":"T7","span":{"begin":40,"end":47},"obj":"Phenotype"},{"id":"T8","span":{"begin":92,"end":99},"obj":"Phenotype"},{"id":"T9","span":{"begin":101,"end":109},"obj":"Phenotype"},{"id":"T10","span":{"begin":138,"end":149},"obj":"Phenotype"},{"id":"T11","span":{"begin":151,"end":159},"obj":"Phenotype"},{"id":"T12","span":{"begin":161,"end":169},"obj":"Phenotype"},{"id":"T13","span":{"begin":171,"end":181},"obj":"Phenotype"},{"id":"T14","span":{"begin":187,"end":201},"obj":"Phenotype"},{"id":"T15","span":{"begin":295,"end":307},"obj":"Phenotype"},{"id":"T16","span":{"begin":553,"end":567},"obj":"Phenotype"},{"id":"T17","span":{"begin":581,"end":593},"obj":"Phenotype"}],"attributes":[{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0012378"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002094"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002315"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0033050"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0002013"},{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0031417"},{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0000509"},{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0002383"}],"text":"9 are fever (85.6%), cough (68.7%), and fatigue (39.4%). Other less common symptoms include dyspnea, headache, loss of appetite, panting, sore throat, vomiting, diarrhea, rhinorrhea, and abdominal pain. The severity of disease in patients depends mainly on the presence of comorbidities such as hypertension, diabetes, and coronary heart disease.12,13 The incubation period is reported to be between 5 and 14 days before disease onset.14 Recent reports indicate that some COVID-19 patients exhibit damage in other organs such as the heart, kidney, eye (conjunctivitis), and brain (encephalitis).15−18 The race is on to develop drugs and treatment options to combat COVID-19, harnessing all of the tools and technologies modern molecular medicine can offer.\nThe genome of SARS-CoV-2 has been fully sequenced19 and shows a high degree of similarity in key genes with other coronaviruses causing respiratory diseases such as SARS-CoV.20 Based on knowledge gathered during the SARS-CoV epidemic, a key target of the virus includes the surface receptor in human cells, angiotensin-converting enzyme II (ACE2), which is required for efficient uptake in host cells.19,21−23\nThe C-terminal domain (i.e., receptor-binding domain of the envelope-embedded spike (S) 1 protein) of SARS-CoV-2 binds ACE2. The molecular details of this interaction have been provided by solving the crystal structure of the complex.24 Because binding of the S protein to ACE2 is critical for the first steps of infection, the most co"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T7","span":{"begin":1137,"end":1143},"obj":"http://purl.obolibrary.org/obo/GO_0098739"},{"id":"T8","span":{"begin":1137,"end":1143},"obj":"http://purl.obolibrary.org/obo/GO_0098657"}],"text":"9 are fever (85.6%), cough (68.7%), and fatigue (39.4%). Other less common symptoms include dyspnea, headache, loss of appetite, panting, sore throat, vomiting, diarrhea, rhinorrhea, and abdominal pain. The severity of disease in patients depends mainly on the presence of comorbidities such as hypertension, diabetes, and coronary heart disease.12,13 The incubation period is reported to be between 5 and 14 days before disease onset.14 Recent reports indicate that some COVID-19 patients exhibit damage in other organs such as the heart, kidney, eye (conjunctivitis), and brain (encephalitis).15−18 The race is on to develop drugs and treatment options to combat COVID-19, harnessing all of the tools and technologies modern molecular medicine can offer.\nThe genome of SARS-CoV-2 has been fully sequenced19 and shows a high degree of similarity in key genes with other coronaviruses causing respiratory diseases such as SARS-CoV.20 Based on knowledge gathered during the SARS-CoV epidemic, a key target of the virus includes the surface receptor in human cells, angiotensin-converting enzyme II (ACE2), which is required for efficient uptake in host cells.19,21−23\nThe C-terminal domain (i.e., receptor-binding domain of the envelope-embedded spike (S) 1 protein) of SARS-CoV-2 binds ACE2. The molecular details of this interaction have been provided by solving the crystal structure of the complex.24 Because binding of the S protein to ACE2 is critical for the first steps of infection, the most co"}

{"project":"LitCovid-sentences","denotations":[{"id":"T25","span":{"begin":57,"end":202},"obj":"Sentence"},{"id":"T26","span":{"begin":203,"end":756},"obj":"Sentence"},{"id":"T27","span":{"begin":757,"end":1166},"obj":"Sentence"},{"id":"T28","span":{"begin":1167,"end":1291},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"9 are fever (85.6%), cough (68.7%), and fatigue (39.4%). Other less common symptoms include dyspnea, headache, loss of appetite, panting, sore throat, vomiting, diarrhea, rhinorrhea, and abdominal pain. The severity of disease in patients depends mainly on the presence of comorbidities such as hypertension, diabetes, and coronary heart disease.12,13 The incubation period is reported to be between 5 and 14 days before disease onset.14 Recent reports indicate that some COVID-19 patients exhibit damage in other organs such as the heart, kidney, eye (conjunctivitis), and brain (encephalitis).15−18 The race is on to develop drugs and treatment options to combat COVID-19, harnessing all of the tools and technologies modern molecular medicine can offer.\nThe genome of SARS-CoV-2 has been fully sequenced19 and shows a high degree of similarity in key genes with other coronaviruses causing respiratory diseases such as SARS-CoV.20 Based on knowledge gathered during the SARS-CoV epidemic, a key target of the virus includes the surface receptor in human cells, angiotensin-converting enzyme II (ACE2), which is required for efficient uptake in host cells.19,21−23\nThe C-terminal domain (i.e., receptor-binding domain of the envelope-embedded spike (S) 1 protein) of SARS-CoV-2 binds ACE2. The molecular details of this interaction have been provided by solving the crystal structure of the complex.24 Because binding of the S protein to ACE2 is critical for the first steps of infection, the most co"}

{"project":"LitCovid-PubTator","denotations":[{"id":"83","span":{"begin":230,"end":238},"obj":"Species"},{"id":"84","span":{"begin":481,"end":489},"obj":"Species"},{"id":"86","span":{"begin":6,"end":11},"obj":"Disease"},{"id":"87","span":{"begin":21,"end":26},"obj":"Disease"},{"id":"88","span":{"begin":40,"end":47},"obj":"Disease"},{"id":"89","span":{"begin":92,"end":99},"obj":"Disease"},{"id":"90","span":{"begin":101,"end":109},"obj":"Disease"},{"id":"91","span":{"begin":111,"end":127},"obj":"Disease"},{"id":"92","span":{"begin":138,"end":149},"obj":"Disease"},{"id":"93","span":{"begin":151,"end":159},"obj":"Disease"},{"id":"94","span":{"begin":161,"end":169},"obj":"Disease"},{"id":"95","span":{"begin":171,"end":181},"obj":"Disease"},{"id":"96","span":{"begin":187,"end":201},"obj":"Disease"},{"id":"97","span":{"begin":295,"end":307},"obj":"Disease"},{"id":"98","span":{"begin":309,"end":317},"obj":"Disease"},{"id":"99","span":{"begin":323,"end":345},"obj":"Disease"},{"id":"100","span":{"begin":472,"end":480},"obj":"Disease"},{"id":"101","span":{"begin":553,"end":567},"obj":"Disease"},{"id":"102","span":{"begin":581,"end":593},"obj":"Disease"},{"id":"103","span":{"begin":665,"end":673},"obj":"Disease"},{"id":"111","span":{"begin":1098,"end":1102},"obj":"Gene"},{"id":"112","span":{"begin":771,"end":781},"obj":"Species"},{"id":"113","span":{"begin":871,"end":884},"obj":"Species"},{"id":"114","span":{"begin":922,"end":930},"obj":"Species"},{"id":"115","span":{"begin":973,"end":981},"obj":"Species"},{"id":"116","span":{"begin":1051,"end":1056},"obj":"Species"},{"id":"117","span":{"begin":893,"end":913},"obj":"Disease"},{"id":"128","span":{"begin":1286,"end":1290},"obj":"Gene"},{"id":"129","span":{"begin":1440,"end":1444},"obj":"Gene"},{"id":"136","span":{"begin":1269,"end":1279},"obj":"Species"},{"id":"137","span":{"begin":1480,"end":1489},"obj":"Disease"}],"attributes":[{"id":"A83","pred":"tao:has_database_id","subj":"83","obj":"Tax:9606"},{"id":"A84","pred":"tao:has_database_id","subj":"84","obj":"Tax:9606"},{"id":"A86","pred":"tao:has_database_id","subj":"86","obj":"MESH:D005334"},{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"MESH:D003371"},{"id":"A88","pred":"tao:has_database_id","subj":"88","obj":"MESH:D005221"},{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"MESH:D004417"},{"id":"A90","pred":"tao:has_database_id","subj":"90","obj":"MESH:D006261"},{"id":"A91","pred":"tao:has_database_id","subj":"91","obj":"MESH:D001068"},{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"MESH:D010608"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"MESH:D014839"},{"id":"A94","pred":"tao:has_database_id","subj":"94","obj":"MESH:D003967"},{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"MESH:D012818"},{"id":"A96","pred":"tao:has_database_id","subj":"96","obj":"MESH:D015746"},{"id":"A97","pred":"tao:has_database_id","subj":"97","obj":"MESH:D006973"},{"id":"A98","pred":"tao:has_database_id","subj":"98","obj":"MESH:D003920"},{"id":"A99","pred":"tao:has_database_id","subj":"99","obj":"MESH:D003324"},{"id":"A100","pred":"tao:has_database_id","subj":"100","obj":"MESH:C000657245"},{"id":"A101","pred":"tao:has_database_id","subj":"101","obj":"MESH:D003231"},{"id":"A102","pred":"tao:has_database_id","subj":"102","obj":"MESH:D004660"},{"id":"A103","pred":"tao:has_database_id","subj":"103","obj":"MESH:C000657245"},{"id":"A111","pred":"tao:has_database_id","subj":"111","obj":"Gene:59272"},{"id":"A112","pred":"tao:has_database_id","subj":"112","obj":"Tax:2697049"},{"id":"A113","pred":"tao:has_database_id","subj":"113","obj":"Tax:11118"},{"id":"A114","pred":"tao:has_database_id","subj":"114","obj":"Tax:694009"},{"id":"A115","pred":"tao:has_database_id","subj":"115","obj":"Tax:694009"},{"id":"A116","pred":"tao:has_database_id","subj":"116","obj":"Tax:9606"},{"id":"A117","pred":"tao:has_database_id","subj":"117","obj":"MESH:D012140"},{"id":"A128","pred":"tao:has_database_id","subj":"128","obj":"Gene:59272"},{"id":"A129","pred":"tao:has_database_id","subj":"129","obj":"Gene:59272"},{"id":"A136","pred":"tao:has_database_id","subj":"136","obj":"Tax:2697049"},{"id":"A137","pred":"tao:has_database_id","subj":"137","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"9 are fever (85.6%), cough (68.7%), and fatigue (39.4%). Other less common symptoms include dyspnea, headache, loss of appetite, panting, sore throat, vomiting, diarrhea, rhinorrhea, and abdominal pain. The severity of disease in patients depends mainly on the presence of comorbidities such as hypertension, diabetes, and coronary heart disease.12,13 The incubation period is reported to be between 5 and 14 days before disease onset.14 Recent reports indicate that some COVID-19 patients exhibit damage in other organs such as the heart, kidney, eye (conjunctivitis), and brain (encephalitis).15−18 The race is on to develop drugs and treatment options to combat COVID-19, harnessing all of the tools and technologies modern molecular medicine can offer.\nThe genome of SARS-CoV-2 has been fully sequenced19 and shows a high degree of similarity in key genes with other coronaviruses causing respiratory diseases such as SARS-CoV.20 Based on knowledge gathered during the SARS-CoV epidemic, a key target of the virus includes the surface receptor in human cells, angiotensin-converting enzyme II (ACE2), which is required for efficient uptake in host cells.19,21−23\nThe C-terminal domain (i.e., receptor-binding domain of the envelope-embedded spike (S) 1 protein) of SARS-CoV-2 binds ACE2. The molecular details of this interaction have been provided by solving the crystal structure of the complex.24 Because binding of the S protein to ACE2 is critical for the first steps of infection, the most co"}

{"project":"2_test","denotations":[{"id":"32519842-31986264-158451","span":{"begin":349,"end":351},"obj":"31986264"},{"id":"32519842-32150748-158452","span":{"begin":435,"end":437},"obj":"32150748"},{"id":"32519842-32247212-158453","span":{"begin":595,"end":597},"obj":"32247212"},{"id":"32519842-32015507-158454","span":{"begin":806,"end":808},"obj":"32015507"},{"id":"32519842-32257431-158455","span":{"begin":931,"end":933},"obj":"32257431"},{"id":"32519842-32015507-158456","span":{"begin":1158,"end":1160},"obj":"32015507"},{"id":"32519842-32333836-158457","span":{"begin":1161,"end":1163},"obj":"32333836"},{"id":"32519842-32142651-158458","span":{"begin":1164,"end":1166},"obj":"32142651"},{"id":"32519842-32275855-158459","span":{"begin":1401,"end":1403},"obj":"32275855"}],"text":"9 are fever (85.6%), cough (68.7%), and fatigue (39.4%). Other less common symptoms include dyspnea, headache, loss of appetite, panting, sore throat, vomiting, diarrhea, rhinorrhea, and abdominal pain. The severity of disease in patients depends mainly on the presence of comorbidities such as hypertension, diabetes, and coronary heart disease.12,13 The incubation period is reported to be between 5 and 14 days before disease onset.14 Recent reports indicate that some COVID-19 patients exhibit damage in other organs such as the heart, kidney, eye (conjunctivitis), and brain (encephalitis).15−18 The race is on to develop drugs and treatment options to combat COVID-19, harnessing all of the tools and technologies modern molecular medicine can offer.\nThe genome of SARS-CoV-2 has been fully sequenced19 and shows a high degree of similarity in key genes with other coronaviruses causing respiratory diseases such as SARS-CoV.20 Based on knowledge gathered during the SARS-CoV epidemic, a key target of the virus includes the surface receptor in human cells, angiotensin-converting enzyme II (ACE2), which is required for efficient uptake in host cells.19,21−23\nThe C-terminal domain (i.e., receptor-binding domain of the envelope-embedded spike (S) 1 protein) of SARS-CoV-2 binds ACE2. The molecular details of this interaction have been provided by solving the crystal structure of the complex.24 Because binding of the S protein to ACE2 is critical for the first steps of infection, the most co"}